A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients

We analyzed the prognostic value of N6-methyladenosine (m6A) regulatory genes in lung adenocarcinoma (LADC) and their association with tumor immunity and immunotherapy response. Seventeen of 20 m6A regulatory genes were differentially expressed in LDAC tissue samples from the TCGA and GEO databases....

Full description

Saved in:
Bibliographic Details
Published in:Aging (Albany, NY.) NY.), 2021-04, Vol.13 (7), p.10034-10057
Main Authors: Wu, Xiao, Sheng, Hongxu, Wang, Luming, Xia, Pinghui, Wang, Yiqing, Yu, Li, Lv, Wang, Hu, Jian
Format: Article
Language:English
Subjects:
Adenocarcinoma of Lung - genetics
Adenocarcinoma of Lung - mortality
Adenocarcinoma of Lung - pathology
Aged
Biomarkers, Tumor - genetics
Databases, Factual
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms - genetics
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Middle Aged
Prognosis
Research Paper
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We analyzed the prognostic value of N6-methyladenosine (m6A) regulatory genes in lung adenocarcinoma (LADC) and their association with tumor immunity and immunotherapy response. Seventeen of 20 m6A regulatory genes were differentially expressed in LDAC tissue samples from the TCGA and GEO databases. We developed a five-m6A regulatory gene prognostic signature based on univariate and Lasso Cox regression analysis. Western blot analysis confirmed that the five prognostic m6A regulatory proteins were highly expressed in LADC tissues. We constructed a nomogram with five-m6A regulatory gene prognostic risk signature and AJCC stages. ROC curves and calibration curves showed that the nomogram was well calibrated and accurately distinguished high-risk and low-risk LADC patients. Weighted gene co-expression analysis showed significant correlation between prognostic risk signature genes and the turquoise module enriched with cell cycle genes. The high-risk LADC patients showed significantly higher PD-L1 levels, increased tumor mutational burden, and a lower proportion of CD8 T cells in the tumor tissues and improved response to immune checkpoint blockade therapy. These findings show that this five-m6A regulatory gene signature is a prognostic biomarker in LADC and that immune checkpoint blockade is a potential therapeutic option for high-risk LADC patients.
ISSN:1945-4589
1945-4589
DOI:10.18632/aging.202761